BONESUPPORT HOLDING AB (SE:BONEX)
:BONEX
BONEX Stock Chart & Stats
kr184.80
-kr10.40(-2.96%)
At close: 4:00 PM EST
kr184.80
-kr10.40(-2.96%)
Day’s Range― - ―
52-Week Rangekr165.00 - kr346.40
Previous CloseN/A
Volume90.84K
Average Volume (3M)318.62K
Market Cap
kr15.13B
Enterprise Valuekr14.77B
Total Cash (Recent Filing)kr377.99M
Total Debt (Recent Filing)kr15.88M
Price to Earnings (P/E)87.1
Beta0.47
Next Earnings
Apr 22, 2026EPS Estimate
0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.67
Shares Outstanding65,859,190
10 Day Avg. Volume295,837
30 Day Avg. Volume318,624
Financial Highlights & Ratios
PEG Ratio14.81
Price to Book (P/B)14.28
Price to Sales (P/S)10.54
P/FCF Ratio56.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)4.75
Revenue Forecast (FY)kr1.51B
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ultra-high gross margins reflect strong product economics and pricing power for CERAMENT. Durable margin advantage supports reinvestment in commercial expansion, funds R&D and absorbs some distribution/tariff friction, making unit economics resilient as volumes scale.
Strong Cash GenerationMaterial positive operating and free cash flow in 2024–2025 with near parity to net income indicates high earnings quality and cash conversion. Combined with very low leverage this provides durable financial flexibility to fund geographic rollout, clinical studies and absorb cyclical pressures.
U.S. Commercial Momentum & FootprintRapid U.S. uptake and distribution into >140 Level 1 trauma centers establishes a durable commercial footprint and trial base for broader surgeon adoption. Scale in the largest market accelerates learning, increases sales per working day and supports long-term growth across product variants.
Bears Say
Regulatory Uncertainty (CERAMENT V)A De Novo pathway lengthens approval timing and raises execution risk for a key product. Delayed market access defers expected revenue and clinical adoption in a new category, limiting near‑term upside and creating uncertainty around when CERAMENT V contributes meaningfully to growth.
Rising Commercial & Distributor CostsIncreasing selling expenses and distributor fees are structurally raising the cost to acquire and service accounts as the company scales internationally. Persistent higher commercial spend can compress operating leverage, making sustained margin improvement more contingent on volume gains.
Early Adoption & Evidence RequirementsExpansion into spine and revision arthroplasty faces multi‑year evidence and clinical adoption cycles. Durable sales growth in these high‑value segments depends on accumulating outcomes data and guideline acceptance, slowing monetization and increasing investment timelines.
BONESUPPORT HOLDING AB News
BONEX FAQ
What was BONESUPPORT HOLDING AB’s price range in the past 12 months?
BONESUPPORT HOLDING AB lowest stock price was kr165.00 and its highest was kr346.40 in the past 12 months.
What is BONESUPPORT HOLDING AB’s market cap?
BONESUPPORT HOLDING AB’s market cap is kr15.13B.
When is BONESUPPORT HOLDING AB’s upcoming earnings report date?
BONESUPPORT HOLDING AB’s upcoming earnings report date is Apr 22, 2026 which is in 10 days.
How were BONESUPPORT HOLDING AB’s earnings last quarter?
BONESUPPORT HOLDING AB released its earnings results on Feb 24, 2026. The company reported kr0.665 earnings per share for the quarter, missing the consensus estimate of kr0.875 by -kr0.21.
Is BONESUPPORT HOLDING AB overvalued?
According to Wall Street analysts BONESUPPORT HOLDING AB’s price is currently Overvalued.
Does BONESUPPORT HOLDING AB pay dividends?
BONESUPPORT HOLDING AB does not currently pay dividends.
What is BONESUPPORT HOLDING AB’s EPS estimate?
BONESUPPORT HOLDING AB’s EPS estimate is 0.98.
How many shares outstanding does BONESUPPORT HOLDING AB have?
BONESUPPORT HOLDING AB has 65,859,190 shares outstanding.
What happened to BONESUPPORT HOLDING AB’s price movement after its last earnings report?
BONESUPPORT HOLDING AB reported an EPS of kr0.665 in its last earnings report, missing expectations of kr0.875. Following the earnings report the stock price went up 3.65%.
Which hedge fund is a major shareholder of BONESUPPORT HOLDING AB?
Currently, no hedge funds are holding shares in SE:BONEX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BONESUPPORT HOLDING AB
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable, moldable, and drillable synthetic bone void filler that includes hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol; CERAMENT G, a gentamicin injectable ceramic bone graft substitute; and CERAMENT V, a vancomycin injectable synthetic bone void filler. It also develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, revision artroplasty, and oncology, as well as bone and foot infections due to diabetes. The company was founded in 1999 and is headquartered in Lund, Sweden.
BONEX Company Deck
BONEX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a broadly positive operational and financial picture: strong underlying sales growth (especially CERAMENT G in the U.S.), high gross margins, solid adjusted profitability and cash generation, plus continued geographic and product expansion (spine launch, De Novo path for CERAMENT V). Offsetting risks include currency translation headwinds that depressed reported growth, headwinds in Germany, rising commercial costs and distributor fees, newly introduced U.S. tariffs, and regulatory timing/uncertainty around CERAMENT V. Early-stage adoption in many newly opened accounts is still developing and some segments (spine, revision arthroplasty) require more evidence. Overall, the positives materially outweigh the challenges, with the company signaling confidence in 2026 constant-currency growth guidance (at least ~35%).View all SE:BONEX earnings summariesTechnical Analysis
Options Prices
Currently, No data available
---